Annovis Bio Achieves 85% Enrollment in Phase 3 Alzheimer’s Trial, Advances Parkinson’s Program
Annovis Bio reports first-quarter progress with 85% enrollment in its pivotal Phase 3 Alzheimer's trial and 40% enrollment in its Parkinson's open-label study, signaling potential regulatory milestones for buntanetap.
Annovis Bio (NYSE: ANVS) has reported first-quarter 2026 business and financial results, highlighting significant progress in its clinical-stage neurodegenerative disease programs. The company announced that it has achieved 85% enrollment in its pivotal Phase 3 Alzheimer’s disease trial and has closed enrollment to new participants after reaching sufficient screening levels to meet enrollment goals. This milestone brings the company closer to potential regulatory submission for its lead drug candidate, buntanetap.
In addition to the Alzheimer’s program, Annovis reported that its Parkinson’s disease open-label extension study has reached 40% enrollment. The company is also advancing new biomarker initiatives and AI-powered digital monitoring to enhance data collection and analysis. These developments underscore Annovis’ commitment to addressing the underlying causes of neurodegeneration through its investigational oral therapy, buntanetap.
Buntanetap (formerly posiphen) inhibits the translation of multiple neurotoxic proteins, including APP, amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By targeting these proteins, Annovis aims to halt disease progression and improve cognitive and motor functions in patients with Alzheimer’s and Parkinson’s diseases.
The progress in enrollment is crucial for the company as it seeks to demonstrate the efficacy and safety of buntanetap in large-scale trials. The Phase 3 Alzheimer’s study is designed to support a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA). Similarly, the Parkinson’s open-label extension study provides long-term safety and efficacy data that could support regulatory filings.
Annovis Bio is headquartered in Malvern, Pennsylvania, and is a Phase 3 clinical-stage biotechnology company. The company’s focus on neurodegenerative diseases positions it at the forefront of a therapeutic area with high unmet medical need. Alzheimer’s disease affects millions worldwide, and Parkinson’s disease is the second most common neurodegenerative disorder.
For more information on the full press release, visit https://ibn.fm/M77X4. To stay updated on the latest news and updates relating to ANVS, visit the company’s newsroom at https://ibn.fm/ANVS. Additional details about Annovis Bio can be found on its website at www.annovisbio.com.